We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement

AMRI, PerkinElmer to Collaborate on Drug Discovery

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

The new AMRI center is part of the Buffalo Medical Innovation and Commercialization Hub (BMIC), a public-private pharmaceutical research and development initiative in Buffalo, New York. The Hub is a collaborative effort that involves SUNY Polytechnic Institute and the State of New York, AMRI, and other industry partners that provide services, platforms, and expertise needed to support drug development projects in academia and industry.

As a result of its collaboration with PerkinElmer, scientists at the BMIC hub will have access to AMRI's chemistry and biology expertise, and they will have access PerkinElmer's informatics technologies and high-content screening capabilities, as well as its cellular imaging and analytics instruments. PerkinElmer will also provide technical and informatics experts to facilitate technological and drug discovery innovations.

"We are pleased to have the opportunity to deliver the platforms, informatics technologies and services to AMRI for its new center of excellence for drug discovery and translational research," Jim Corbett, PerkinElmer's president, human health, said in a statement. "We look forward to supporting the BMIC's expansion by working closely with additional companies that establish lab facilities at this site."